閉経後膣萎縮（PVA）：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology 20
3.1.1 Etiology 20
3.1.2 Pathophysiology 20
3.1.3 Prognosis 21
3.1.4 Quality of Life 21
3.2 Symptoms 21
4 Epidemiology 23
4.1 Risk Factors and Comorbidities 24
4.1.1 Sexual inactivity increases symptoms of postmenopausal vaginal atrophy 24
4.1.2 Smoking causes early menopause and exacerbates atrophic vaginal changes 24
4.1.3 The prevalence of postmenopausal vaginal atrophy is higher in women who have undergone cancer treatment 25
4.2 Global and Historical Trends 25
4.3 Forecast Methodology 27
4.3.1 Sources Used 30
4.3.2 Forecast Assumptions and Methods 31
4.3.3 Sources Not Used 34
4.4 Incident/Prevalent Cases of Postmenopausal Vaginal Atrophy 34
4.5 Discussion 36
4.5.1 Conclusions on Epidemiological Trends 36
5 Disease Management 38
5.1 Treatment Overview 38
5.2 Treatment Guidelines 38
5.3 Disease Management 39
5.4 United States 42
5.4.1 Diagnosis 42
5.4.2 Clinical Practice 42
5.5 France 43
5.5.1 Diagnosis 43
5.5.2 Clinical Practice 43
5.6 Germany 44
5.6.1 Diagnosis 44
5.6.2 Clinical Practice 44
5.7 Italy 45
5.7.1 Diagnosis 45
5.7.2 Clinical Practice 45
5.8 Spain 45
5.8.1 Diagnosis 45
5.8.2 Clinical Practice 46
5.9 United Kingdom 46
5.9.1 Diagnosis 46
5.9.2 Clinical Practice 46
5.10 Japan 47
5.10.1 Diagnosis 47
5.10.2 Clinical Practice 47
6 Competitive Assessment 48
6.1 Overview 48
6.2 Strategic Competitor Assessment 49
6.3 Product Profiles – Major Brands 50
6.3.1 Vagifem (estradiol vaginal tablet) 50
6.3.2 Estring (estradiol vaginal ring) 54
6.3.3 Premarin (conjugated estrogens cream) 57
6.3.4 Estrace (17 beta-estradiol cream) 60
6.3.5 Colpotrophine (promestriene vaginal cream/ovule) 63
6.3.6 Minor Therapeutic Classes 66
7 Opportunity and Unmet Need 68
7.1 Unmet Needs 69
7.1.1 Disease Awareness and Increased Treatment-Seeking Behavior 69
7.1.2 Alternatives to Estrogen Therapy/Improved Drug Safety Profiles 70
7.1.3 Convenience and Patient Compliance 71
7.1.4 Unmet Needs Gap Analysis 71
7.1.5 Opportunity 1: Dosing and Administration 72
7.1.6 Opportunity 2: Compliance and Convenience 73
7.1.7 Opportunity 3: Safety 74
8 Pipeline Assessment 75
8.1 Overview 75
8.2 Clinical Trial Mapping 76
8.2.1 Clinical Trials by Country 76
8.2.2 Clinical Trials by Phase and Trial Status 77
8.3 Promising Drugs in Clinical Development 79
8.3.1 Osphena (ospemifene) 80
8.3.2 Vaginorm (prasterone, intravaginal DHEA) 85
8.3.3 BZA/CE (bazedoxifene + conjugated estrogens) 91
8.3.4 Forecast 96
9 Current and Future Players 97
9.1 Overview 97
9.2 Trends in Corporate Strategy 100
9.3 Company Profiles 101
9.3.1 Pfizer 101
9.3.2 Shionogi 103
9.3.3 Novo Nordisk 105
9.3.4 Actavis 107
9.3.5 Bayer AG 109
10 Market Outlook 111
10.1 Global Markets 111
10.1.1 Forecast 111
10.1.2 Drivers and Barriers – Global Issues 113
10.2 United States 115
10.2.1 Forecast 115
10.2.2 Key Events 117
10.2.3 Drivers and Barriers 117
10.3 France 119
10.3.1 Forecast 119
10.3.2 Key Events 121
10.3.3 Drivers and Barriers 121
10.4 Germany 123
10.4.1 Forecast 123
10.4.2 Key Events 125
10.4.3 Drivers and Barriers 125
10.5 Italy 127
10.5.1 Forecast 127
10.5.2 Key Events 129
10.5.3 Drivers and Barriers 129
10.6 Spain 131
10.6.1 Forecast 131
10.6.2 Key Events 133
10.6.3 Drivers and Barriers 133
10.7 United Kingdom 135
10.7.1 Forecast 135
10.7.2 Key Events 136
10.7.3 Drivers and Barriers 137
10.8 Japan 139
10.8.1 Forecast 139
10.8.2 Key Events 140
10.8.3 Drivers and Barriers 141
11 Appendix 142
11.1 Bibliography 142
11.2 Abbreviations 156
11.3 Methodology 159
11.4 Forecasting Methodology 159
11.4.1 Diagnosed postmenopausal atrophy patients 159
11.4.2 Percent Drug-Treated Patients 160
11.4.3 Launch and Patent Expiry Dates 160
11.4.4 General Pricing Assumptions 161
11.4.5 Individual Drug Assumptions 162
11.4.6 Generic Erosion 164
11.4.7 Pricing of Pipeline agents 165
11.5 Physicians and Specialists Included in This Study 165
11.6 About the Authors 167
11.6.1 Author 167
11.6.2 Epidemiologists 167
11.6.3 Global Director of Epidemiology and Clinical Trials Analysis 168
11.6.4 Director of Oncology, Hematology and Gender Health 168
11.6.5 Global Head of Healthcare 169
11.7 About GlobalData 170
11.8 Disclaimer 170